Table 2: New cases and age-standardized incidence rates (ASIR) of cancer in children aged 0 to 14 years by sex, 2001-2006, Canada (French, CSV)
Table 2: New cases and age-standardized incidence rates (ASIR) of cancer in children aged 0 to 14 years by sex, 2001-2006, Canada: French CSV file you can open as a table, filter, chart and export up to 10,000 rows. From Public Health Agency of Canada, updated Mar 2020.
- Format
- CSV
- Access
- Table on demand (prepared when opened)
- Publisher-reported update
- 2020-03-02
The Cancer in Young People in Canada (CYP-C) program is a national, population-based surveillance system that collects health and treatment information on each child/youth under the age of fifteen diagnosed with cancer in Canada. These datasets contain the information presented in the tables and figures describing the demographics, diagnosis, treatment, location and timing of care, and outcomes in children diagnosed with cancer from 2001-2006 which were published in the following report: The Public Health Agency of Canada. (2017). Cancer in Young People in Canada: A Report from the Enhanced Childhood Cancer Surveillance System. Available online at https://www.canada.ca/en/health-canada/services/publications/science-research-data/cancer-young-people-canada-surveillance-2017.html
Data overview
- Formats
- CSV
- File languages
- French
- Available actions
- Explore table (prepared automatically) · Access original file
Sample rows
The first 10 rows, as CanQuery read them from the start of the publisher's file on 2026-11-01.
| Type de cancer | Nouveaux cas, Garçons | Nouveaux cas, Filles | Nouveaux cas, Total | G/F* | TISA (pour 1 000 000 d'enfants), Garçons | TISA (pour 1 000 000 d'enfants), Filles | TISA (pour 1 000 000 d'enfants), Total |
|---|---|---|---|---|---|---|---|
| Tous les cancers combinés | 2810 | 2320 | 5125 | 1.2 | 163 | 141.2 | 152.4 |
| I Leucémies, syndromes myéloprolifératifs et syndromes myélodysplasiques | 895 | 710 | 1610 | 1.3 | 53 | 43.9 | 48.6 |
| I a) Leucémies lymphoïdes | 750 | 550 | 1300 | 1.4 | 44.2 | 34.3 | 39.4 |
| I b) Leucémies myéloïdes aiguës | 105 | 100 | 205 | 1 | 5.9 | 6.2 | 6 |
| I c) Syndromes myéloprolifératifs chroniques | 10 | 20 | 30 | 0.7 | 0.6 | 0.9 | 0.8 |
| I d) Syndromes myélodysplasiques et autres syndromes myéloprolifératifs | 25 | 30 | 55 | 0.9 | 1.6 | 1.9 | 1.8 |
| I e) Leucémies non précisées et autres leucémies précisées | 10 | 10 | 20 | 1.1 | 0.6 | 0.6 | 0.6 |
| II Lymphomes et tumeurs réticuloendothéliales | 440 | 245 | 685 | 1.8 | 24.5 | 14.2 | 19.5 |
| II a) Lymphome de Hodgkin | 125 | 95 | 220 | 1.3 | 6.5 | 5 | 5.8 |
| II b) Lymphomes non hodgkiniens (sauf le lymphome de Burkitt) | 130 | 65 | 195 | 2 | 7.1 | 3.7 | 5.5 |